References
McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825–33.
Tobinai K. Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan. Int J Hematol. 2002;76:411–419.
Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med. 2003;348:2690–2691.
Riegert-Johnson DL, Godfrey JA, Myers JL, et al. Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis. 2002;8:186–191.
Kurakawa E, Kasuga I, Ishizuka S, et al. Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: first case report. Jpn J Clin Oncol. 2001;31:284–286.
Onishi H, Yokoyama A, Yasuhara Y, et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax. 2003;58:872–875..
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Hiraga, J., Kondoh, Y., Taniguchi, H. et al. A Case of Interstitial Pneumonia Induced by Rituximab Therapy. Int J Hematol 81, 169–170 (2005). https://doi.org/10.1532/IJH97.04163
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1532/IJH97.04163